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The introduction and widespread implementation of newborn bloodspot screening (NBS) for
cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many
countries of the world. It represents a paradigm shift in the diagnostic pathway for these families.
In contrast to a clinical diagnosis, infants are now referred for diagnostic testing after a positive NBS
result and, apart from a small proportion who present with bowel obstruction (meconium ileus),
CF infants have no or only minimal clinical manifestation of the disease in the early days of life. Clinical
symptoms can appear over the first few weeks, for example, insufficient weight gain, fatty stools or
salt loss syndrome, but are often insidious and difficult to recognise.
The introduction of NBS has enabled the provision of early appropriate treatment (pancreatic
enzyme replacement therapy, fat-soluble vitamins, salt supplementation and antibiotics) to prevent
manifestations of the disease. In the near future, early diagnosis will facilitate the prompt use of new
cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies that correct the basic
underlying molecular defect.
NBS for CF has been a global success but continues to raise questions with many varied
approaches and the development of new technologies, in particular the ability to undertake extensive
gene examination. It is still valid to ask many questions:
• What is the best protocol to achieve high sensitivity and specificity?
• Should extensive genetic analysis be part of this algorithm, which enables the identification of
many more CFTR variants?
• How to evaluate and manage inconclusive cases with a borderline sweat test or CFTR variants
with unclear clinical relevance?
• What is the optimal approach to inform and counsel the parents about the NBS results and
inconclusive findings?
These questions are not easy to answer and require a balanced solution that reflects the local
health care system and may appropriately result in different answers around the globe.
The aim of this series of articles was to compile the current state of knowledge on NBS for CF and
the questions arising from it. Using the framework of the network of the Newborn Screening Working
Group (NSWG) of the European CF Society (ECFS), we approached colleagues from all over the world
to submit articles for peer review. On the initiative of the International Journal of Newborn Screening
(IJNS), the opportunity arose to realize this project, and we would like to take this opportunity to thank
the authors for their excellent contributions and the IJNS for their support and cooperation. We feel
the resulting series of articles provides a state-of-the-art evaluation of the current status of NBS for CF
and provides much insight into the questions above and a path to improve quality across the globe.
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The history of newborn bloodspot screening for CF is recorded by Georges Travert and Mary and
Anthony Heeley, all of whom played an important role in these early developments. They cover the
early use of the immune-reactive trypsinogen (IRT) assay, the challenges they and others faced and
how they were overcome [1].
Lutz Naehrlich describes how early diagnosis, multidisciplinary care and optimized and preventive
treatments have improved the outlook for people with CF. From his position as Director of the European
Registry, he is able to give a clear picture of the changing face of CF, and the direct impact of NBS on
this landscape [2].
One of the major challenges in the field of NBS for CF has been the collection of robust and
comparable data across countries and regions. New Zealand was the first country to establish NBS
for CF and Natasha Heather and Dianne Webster are well placed to reflect on the importance and
challenges of collecting the correct metrics [3]. They highlight the critical importance of this if the
quality of this public health initiative is to improve.
Virginie Scotet, Hector Gutierrez and Philip M. Farrell give an overview about the current situation
of NBS for CF across the globe [4]. Each region has typically undertaken CF NBS after analysis of the
advantages, costs and challenges, particularly regarding the relationship of benefits to risks. The review
describes the lessons learned from the journey toward universal screening wherever CF is prevalent
and an analytical framework for application in those undecided regions.
This complements the next article, in which Rachel Armstrong, Lucy Frith, Fiona Ulph and Kevin
Southern consider NBS for CF from a bioethical perspective [5]. They report in detail all possible
outcomes from NBS for CF and place these in an ethical framework. Placing these in the context of the
genetic profile of the population screened, the geography of the region and the healthcare resources
available, they propose an approach engaging with stakeholders to determine the best protocol for
a region.
Olaf Sommerburg and Jutta Hammermann describe in their review the strengths and weaknesses
of pancreatitis-associated protein (PAP) in the algorithm of NBS for CF [6]. This biochemical test has
emerged as an adjunct to IRT measurement, but the relationship is complex and is reviewed in detail
by these authors who have considerable experience through implementing this assay as part of the
protocol in Germany.
Anne Bergougnoux, Maureen Lopez and Emmanuelle Girodon give a summary of the role of
DNA analysis in the CF screening programme. Their work in the national French laboratory gives
them a unique insight into the challenges of incorporating genetic testing, especially extended gene
analysis (EGA) [7].
A consequence of NBS for CF is the identification of infants with a positive screening test but an
inconclusive diagnostic testing. Anne Munck led the European consensus exercise to better define the
evaluation and management of these infants, in addition to leading the French research project that
monitored outcomes. She places these results in the context of other work from around the globe [8].
The processing of a positive NBS result for CF not only consists of the screening part in the
laboratory but also the interface between the family and healthcare, and ultimately the CF team. This is
a complex process reviewed by Jürg Barben and Jane Chudleigh, both of whom have undertaken
extensive research projects examining these issues [9]. It is clear that this is an area that needs
considerable improvement across the globe and the authors review evidence of good practice and
propose a roadmap to improve the quality of this difficult process.
Consistent with the article above is a detailed review of the psychological impact of NBS for
CF by Jane Chudleigh and Holly Chinnery [10]. A better understanding of the journey that the
families of infants with a positive NBS result go on enables CF teams to predict and ameliorate
unnecessary distress.
Again we thank all the authors; there is much to celebrate in the field of NBS for CF, but clearly
still work to do, and this experienced faculty of authors has provided a series of state-of-the-art articles
to help achieve that goal. In addition, we would like to thank the 19 experts who provided high-quality
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peer review (sometimes twice) for this series. We were extremely grateful for their comprehensive and
timely contributions, which were important for the overall quality of the series.
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